metastatic renal cell carcinoma

ʻO ka maʻi maʻi maʻi metastatic renal cell carcinoma (mRCC) he ʻano maʻi maʻi maʻi ʻaʻai i laha i nā wahi ʻē aʻe o ke kino. ʻOkoʻa nā koho lapaʻau ma muli o ke kahua a me nā ʻano kikoʻī o ka maʻi kanesa, akā hoʻokomo pinepine ʻia ka lāʻau lapaʻau, immunotherapy, ʻokiʻoki, a me ka radiation therapy. He mea koʻikoʻi ka ʻike mua a me nā hoʻolālā lapaʻau hou no ka hoʻomaikaʻi ʻana i nā hopena no nā maʻi me ka mRCC. Hāʻawi kēia alakaʻi i kahi hiʻohiʻona hohonu o ka mRCC, e uhi ana i kāna mau kumu, nā hōʻailona, ​​​​nā hōʻailona, ​​​​nā koho lapaʻau, a me ka wānana. Hoʻomaka ia ma ka uhi o ka tubule convoluted proximal, nā paipu liʻiliʻi loa i loko o ka puʻupaʻa e kānana i ke koko a wehe i nā mea ʻōpala. Ke hele ka RCC metastasizes, ʻo ia hoʻi, ua haʻihaʻi nā keʻena maʻi maʻi mai ke koko mua i loko o ka puʻupaʻa a laha i nā ʻāpana ʻē aʻe o ke kino, e like me ka māmā, iwi, lolo, a i ʻole ate. I ka wā i laha ai, ua hoʻokaʻawale ʻia ʻo ia metastatic renal cell carcinoma (mRCC).Na kumu a me na mea pilikia o ka ma'i ma'i ma'i ma'i Renal 'A'ole i maopopo mau ke kumu o ka RCC, akā hiki i kekahi mau mea ke ho'onui i ka pilikia o ka ulu 'ana i ka ma'i. ʻObesity: ʻO ka lilo ʻana i ke kaumaha a i ʻole ka momona e pili ana i kahi pilikia nui. Ke Koko Kiʻekiʻe: Hiki i ke koko kiʻekiʻe ke hōʻino i nā puʻupaʻa a hoʻonui i ka maʻi kanesa. Moʻolelo ʻohana: ʻO ka loaʻa ʻana o ka moʻolelo ʻohana o RCC e hoʻonui i kou pilikia. ʻO kekahi mau maʻi hoʻoilina, e like me ka maʻi von Hippel-Lindau (VHL), Birt-Hogg-Dube syndrome, a me ka maʻi maʻi maʻi papillary renal cell carcinoma, ua pili pū me ka ʻoi aʻe o ka pilikia. ʻO ka maʻi maʻi kīpē kiʻekiʻe a i ʻole ka maʻi dialysis: ʻO ka poʻe me ka maʻi maʻi maʻi maʻi, ʻoi aku ka nui o ka poʻe e hele ana i ka maʻi dialysis, ʻoi aku ka nui o ka pilikia. ʻIke ʻia i kekahi mau mea kemika: Ua hoʻopili ʻia ka ʻike ʻana i ka hana i ka cadmium, trichloroethylene, a me kekahi mau lāʻau herbicides i RCC. Nā hōʻailona o ka Metastatic Renal Cell Carcinoma ʻAʻohe mau hōʻailona o ka RCC mua. I ka ulu ʻana a i ʻole ka metastases o ke koko, hiki ke ʻike ʻia nā hōʻailona. Hiki ke ʻokoʻa kēia ma muli o kahi i laha ai ka maʻi kanesa, akā nā hōʻailona maʻamau o metastatic renal cell carcinoma ʻO ke koko i loko o ka mimi (hematuria) ʻEha mau ma ka ʻaoʻao a i ʻole ke kua He puʻupuʻu a nui paha ma ka ʻaoʻao a i ʻole ke kua. metastatic renal cell carcinoma ʻO ka mea maʻamau ka hui pū ʻana o nā hoʻokolohua kino, nā hoʻokolohua kiʻi, a me nā biopsies. Nānā Kino: E hana ke kauka i kahi hoʻokolohua kino e nānā i nā mea ʻino. Nā Ho'āʻo Kiʻi: CT Scan: Hāʻawi kahi CT scan i nā kiʻi kikoʻī o nā puʻupaʻa a me nā ʻiʻo a puni a hiki ke kōkua i ka ʻike ʻana i nā ʻōpū a nānā i ko lākou nui a me ko lākou wahi. MRI: Hiki i kahi MRI ke hāʻawi i nā kiʻi kikoʻī hou aʻe a hoʻohana pinepine ʻia e loiloi i ka nui o ka maʻi kanesa. Iwi: Hoʻohana ʻia ka ʻimi iwi e nānā inā ua laha ke kanesa i nā iwi. PET Scan: Hiki i ka PET scan ke kōkua i ka ʻike ʻana i nā maʻi maʻi maʻi a puni ke kino. ʻO ka biopsy: ʻO ka biopsy ka wehe ʻana i kahi mea liʻiliʻi o ka ʻiʻo mai ka puʻupaʻa a i ʻole kahi pae metastatic no ka nānā ʻana ma lalo o kahi microscope. Hōʻoia kēia i ka hōʻailona o RCC a kōkua i ka hoʻoholo ʻana i ke ʻano kikoʻī o RCC. Nā Koho Lapaʻau no ka Metastatic Renal Cell CarcinomaLaʻau no ka metastatic renal cell carcinoma pili i kekahi mau kumu, e like me ka nui o ka maʻi kanesa, ke olakino holoʻokoʻa o ka mea maʻi, a me nā ʻano kikoʻī o ka ʻōpū. ʻO nā koho lapaʻau maʻamau: ʻO ka Therapy ʻO nā lāʻau lapaʻau i manaʻo ʻia e hoʻopaʻa i nā molekole kikoʻī e pili ana i ka ulu ʻana o ka cell cancer a me ke ola. Hiki i kēia mau lāʻau lapaʻau ke hoʻolōʻihi i ka ulu ʻana o ka maʻi kanesa a hoʻomaikaʻi i ka nui o ke ola. ʻO nā lāʻau lapaʻau maʻamau i hoʻopaʻa ʻia no ka mRCC ʻo ia ka: VEGF inhibitors (e laʻa, sunitinib, sorafenib, pazopanib, axitinib, cabozantinib): Ke ālai nei kēia mau lāʻau lapaʻau i ke ala vascular endothelial growth factor (VEGF), he mea nui ia no ka hoʻokumu ʻana o nā moku koko i loko o nā ʻōpū. ʻO nā mea hoʻopaneʻe mTOR (e laʻa, everolimus, temsirolimus): Ke ālai nei kēia mau lāʻau lapaʻau i ke ala o ka rapamycin (mTOR) i hoʻopaʻa ʻia i ka mammalian, e pili ana i ka ulu ʻana o nā cell a me ka metabolism. Ua hōʻike kēia mau lāʻau i nā hopena maikaʻi i ka mālama ʻana i ka mRCC. ʻO nā immunotherapies maʻamau no ka mRCC: ʻO nā mea hoʻopaneʻe Checkpoint (e laʻa, nivolumab, pembrolizumab, ipilimumab): Hoʻopaʻa kēia mau lāʻau i nā protein i nā cell immune e pale iā lākou mai ka hoʻouka ʻana i nā cell cancer. Hiki i kēia ke kōkua i ka hōʻoluʻolu i nā hōʻailona a hoʻomaikaʻi i ka maikaʻi o ke ola. ʻO ka nephrectomy Cytoreductive e pili ana i ka wehe ʻana i ka maʻi maʻi maʻi mua inā ua laha ke kanesa i nā wahi ʻē aʻe o ke kino. Hiki i kēia ke hoʻomaikaʻi i ka maikaʻi o nā lāʻau lapaʻau ʻē aʻe. Hoʻohana ʻo Radiation therapy i nā kukuna ikaika kiʻekiʻe e pepehi i nā maʻi kanesa. Hiki ke hoʻohana ʻia no ka hoʻomaha ʻana i ka ʻeha a i ʻole nā ​​hōʻailona ʻē aʻe i hoʻokumu ʻia e nā maʻi maʻi metastatic, ʻoi aku ka nui o nā iwi a i ʻole ka lolo. ʻO nā maʻi me metastatic renal cell carcinoma hiki ke noʻonoʻo e komo i kahi hoʻokolohua lapaʻau no ka loaʻa ʻana o nā lāʻau lapaʻau ʻokiʻoki. Prognosis of Metastatic Renal Cell Carcinoma metastatic renal cell carcinoma ʻokoʻa ma muli o kekahi mau kumu, me ka nui o ka maʻi kanesa, ke olakino holoʻokoʻa o ka mea maʻi, a me ka pane ʻana i ka lāʻau lapaʻau. Ma ka mōʻaukala, ʻaʻole maikaʻi ka wānana o ka mRCC, akā ua hoʻomaikaʻi maikaʻi ʻia ka holomua o ka lāʻau lapaʻau a me ka immunotherapy i nā hopena no nā maʻi he nui. ʻO nā mea e hiki ke hoʻoikaika i ka prognosis, ʻo ia ka International Metastatic Renal Cell Carcinoma Database Consortium (IMDC), ka mea e noʻonoʻo ana i nā mea e like me ka manawa mai ka maʻi ʻana a hiki i ka mālama ʻana, ke kūlana hana, nā pae hemoglobin, nā pae calcium, ka helu neutrophil, a me ka helu platelet. Noho me Metastatic Renal Cell Carcinoma. metastatic renal cell carcinoma hiki ke paʻakikī, ma ke kino a me ka naʻau. He mea nui ka loaʻa ʻana o kahi ʻōnaehana kākoʻo ikaika a e hana i nā hana e mālama i nā hōʻailona a me nā hopena ʻaoʻao o ka lāʻau lapaʻau. Aia paha kēia: Hoʻoponopono ʻeha Kākoʻo meaʻai Ka hoʻomaʻamaʻa a me ka hoʻomaʻamaʻa kino Ka ʻōlelo aʻo a i ʻole nā hui kākoʻo ʻO ke kuleana o Shandong Baofa Cancer Research InstituteAt Shandong Baofa Cancer Research Institute, ua hoʻolaʻa ʻia mākou i ka hoʻolako ʻana i ka mālama maʻi maʻi āpau a me nā mea hou. Kūpaʻa mākou i ka holomua ʻana i ka noiʻi maʻi maʻi a me ka hāʻawi ʻana i nā maʻi i nā lāʻau lapaʻau maikaʻi loa. ʻO kā mākou hui o nā oncologists akamai, nā kauā, a me nā limahana kākoʻo e hana pū i ka hoʻomohala ʻana i nā hoʻolālā lapaʻau pilikino no kēlā me kēia maʻi me ka manaʻo i ka hoʻomaikaʻi ʻana i ka maikaʻi o ke ola a me ke ola holoʻokoʻa. Hoʻoikaika mākou e hāʻawi i nā holomua hou loa i ka mālama ʻana i ka maʻi kanesa, me nā lāʻau lapaʻau i manaʻo ʻia, immunotherapies, a me nā hoʻokolohua lapaʻau. metastatic renal cell carcinoma ke hoʻomau nei, me ka pahuhopu e hoʻomohala i nā lāʻau lapaʻau hou a ʻoi aku ka maikaʻi. ʻO nā wahi o ka noiʻi i kēia manawa: Ke kūkulu nei i nā lāʻau lapaʻau hou a me nā immunotherapies Ka ʻike ʻana i nā biomarkers hiki ke wānana i ka pane ʻana i ka mālama ʻana.